Type 2 diabetes

Researchers have found that the gut microbiome could help identify people at increased risk of developing type 2 diabetes years before the diagnosis.

A lengthy trial robbing adults of 90 minutes of sleep a night has uncovered the effect even this small amount of lost shut-eye has on the waistline after little more than a month. It also increased the risk factors for chronic disease.

A team of researchers in China has sifted through the noise in what amounts to the most comprehensive review yet, and the results are both sobering and intriguing.

GLP-1 drugs like Ozempic and Wegovy are already known for treating type 2 diabetes and helping with weight loss. Now, a new study suggests they may also improve some of the most difficult complications to treat in type 2 diabetes.

A new review presents comprehensive and convincing research that ties common sugar substitutes to metabolic disturbances that begin in the gut and then flow throughout the body. It also highlights issues of food-label transparency in the US.

The type 2 diabetes drug taken by an estimated 20 million Americans has long been thought of doing its heavy lifting in the liver, suppressing glucose production. But research has found it's actually unleashing its power in another part of the body.

Adding to the growing body of research that proves our microbiome is a powerful ally in fighting disease, scientists have found that an easy-to-get nutrient in our food causes our guts to produce powerful insulin-regulating compounds.

Scientists have made a major breakthrough in understanding how fat cells grow in size, in response to accommodating larger droplets of fat. The findings unlock a new path in tackling obesity, by reducing the amount of fat our cells can store away.

Millions of people with type 2 diabetes might actually be undermining their efforts to improve their health, with researchers demonstrating that the commonly prescribed metformin blocks the cardiovascular benefits normally gained through exercise.

A large international study of more than 23,000 patients has found that common medicines used to treat high blood pressure and cholesterol, as well as heartburn, may be impacting cancer treatment effectiveness.

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and inflammation, potentially offering a powerful new way to protect the heart and improve metabolism.

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.